AstraZeneca on hunt for deals, but may not stay in vaccines

LONDON - AstraZeneca may not stay in the vaccine business in the long run and is looking to buy small and mid-sized companies specialising in oncology and cardiovascular treatments, Chief Executive Pascal Soriot said in a Reuters Newsmaker interview on Tuesday. Production delays, probes by regulators following rare cases of severe side effects and concerns about its relatively short shelf life compared with other shots have stymied adoption of AstraZeneca's COVID-19 vaccine. Now, in the third year of the pandemic amid a global vaccine supply glut, its use has diminished in much of the developed world as countries have inoculated much of their populations and prefer Pfizer and Moderna's mRNA vaccines as boosters. AstraZeneca's COVID vaccine has still not attained U.S. approval. "I cannot be sure the company will remain in the COVID vaccines business," Soriot said in the interview, adding it may also shelve plans to build a broader vaccines portfolio. AstraZeneca is looking for bolt-on acquisitions, Soriot added. "We always look for external opportunities," he said. The CEO has presided over a quadrupling of AstraZeneca's share price in his decade at the helm. "I can keep doing this job for many years," he said. The 63-year old was once seen as a natural successor to outgoing Chairman Leif Johansson. But in July, Soriot quashed speculation he was planning to retire any time soon, saying he expected to work with the company's newly announced chairman-designate Michel Demare for many years to come. Soriot was tasked with turning around a troubled AstraZeneca - hit by a string of key patent losses and a spate of clinical trial failures - in October 2012, following a stint at pharma peer Roche. With the Frenchman at the helm, the fortunes of the London-listed Anglo-Swedish drugmaker changed dramatically after he sharpened focus on speciality medicines and the lucrative field of oncology, made acquisitions to refill the company's medicine cabinet, fended off a hostile takeover from U.S. pharma giant Pfizer, and invested heavily in R&D to improve the company's lacklustre drug development success rate. However, he warned on Tuesday that fewer innovative medicines would be developed going forward due to new U.S. drug price laws. Asked about inflationary pressures, Soriot said: "We are going to have to become more innovative and productive. We can't expect our selling prices to go up." (Reporting by Aimee Donnellan and Natalie Grover, Editing by Mark Potter)

AstraZeneca on hunt for deals, but may not stay in vaccines

DISCOVER MORE

Egypt’s Health Minister discuss bilateral cooperation with an Italian delegation

Saudi: Aldawaa Medical Services unveils 28% higher profits in 2022, dividends for H2-22

Saudi: SPIMACO shifts to over $45.6mln losses in 2022

UAE: Breakthrough by Emirati engineers could make prosthetic limbs cheaper, more easily available

DAHC, AXDEV Global, Pfizer Global Medical Grants partner for chronically ill patients' enhanced care

Moderna rebuked over plan to hike Covid vaccine to $130

Saudi: Mouwasat logs $159.73mln profits in 2022

Egypt seeks cooperation with Huawei Technologies to improve healthcare system

GCC central banks track US Fed move; hike key rates by 25bps

UAE exchange firm Al Ansari upsizes IPO on strong investor demand

Dubai's Meraas to build new residential towers in Design District

VIDEO: LSE-listing will facilitate more funding opportunities for us, Dar Global CEO

Dubai’s Emirates to add value, support Air India – Tim Clark

China to promote vaccine development, new medicines

Not just vaccines, we need clean air to prevent another pandemic

Not just healthcare, patients need better access to medicines

WHO urges malaria funding boost as deaths stay stubbornly high

Negotiations on global pandemic treaty to start in February: WHO

LATEST VIDEO

VIDEO: LSE-listing will facilitate more funding opportunities for us, Dar Global CEO

ZAWYA COVERAGE

Will gold face more downside or upside after Fed's rate hike?

Kenya signs $250mln deal with UK to boost food production

PODCAST: IFC is ready to back governments privatisation plans with capital

UAE's Presight AI to debut on Abu Dhabi Securities Exchange next week

Yellen chairs closed US Financial Stability Oversight Council meeting

US to implement asylum deal with Canada on Saturday, final rule says

Fed's Bullard: "Swift" US response to bank stress keeps rate focus on inflation

France's Macron says he will not yield to violence after demonstrations against pensions reform

Euro zone banks resilient, ECB can provide liquidity if needed -Lagarde

THE BRI REPORT

China is reshaping the Belt and Road Initiative ahead of a post-pandemic era

DISCOVER MORE

LATEST VIDEO

ZAWYA NEWSLETTERS

ZAWYA COVERAGE